Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06913634

Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the Compassionate Use Phase

Luspatercept represents the first and only erythroid maturation agent (EMA) approved by the European Commission (EC) and the Food and Drug Administration (FDA) capable of enhancing advanced erythrocyte maturation.

The efficacy of luspatercept was demonstrated in the phase III clinical trial called "BELIEVE." More than 200 Italian patients with transfusion- dependent beta thalassemia aged ≥18 years who had no approved therapeutic alternatives to improve their clinical course were considered eligible for the 'compassionate' use program related to luspatercept and most of them received at least one dose of the drug before it was dispensed by the National Health System (NHS), after approval by the pharmaceutical company and the Ethics Committee of the Clinical Center in which they were being followed.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Thalassemia Major Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Thalassemia beta-Thalassemia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Cagliari, Ospedale Pediatrico Microcitemico, via Jenner sn, 09121 Cagliari -

Cagliari, CA, 09121, Italy

About this study

One month after the publication in the Official Gazette of the Italian Republic of the AIFA determination of price and reimbursement for the treatment indication covered by the program, those who were still on treatment and were, in clinical judgment, eligible to continue it, continued to receive the drug through dispensation by the NHS.

Because access to the compassionate phase was less restrictive than access to that in formal clinical trials and the patients included particularly representative of real life, collecting data on clinical characteristics at baseline, safety, and efficacy is critical to enriching the information available on this new therapy. Continuing to collect efficacy, safety, and tolerability information beyond the compassionate phase is also essential for a more complete and accurate assessment, given the short duration of 'compassionate' treatment for a portion of the patients under study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who received at least one dose of luspatercept in the compassionate phase

Exclusion criteria

  • Subjects who are not willing or able to sign the informed consent.

Treatment and study plan

Luspatercept (ACE-536)

Drug

Luspatercept (ACE-536)

Primary outcomes

  1. To evaluate safety of luspatercept, number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 12-week interval period of luspatercept treatment.

    To evaluate safety of luspatercept in subjects with transfusion-dependent beta thalassemia who received at least one dose of the drug in the compassionate use phase including the post- marketing authorisation phase in those who continued to receive it.

  2. To evaluate tolerability of luspatercept, number of participants with treatment-related adverse events as assessed by CTCAE v4.0"

    Time frame: 12-week interval period of luspatercept treatment.

    To evaluate tolerability of luspatercept in subjects with transfusion-dependent beta thalassemia who received at least one dose of the drug in the compassionate use phase including the post- marketing authorisation phase in those who continued to receive it.

  3. To evaluate efficacy of luspatercept, Number of subjects who showed a ≥ 33% reduction from baseline in the number of transfused blood units during any 12-week interval period of luspatercept treatment

    Time frame: 12-week interval period of luspatercept treatment.

    To evaluate efficacy of luspatercept in subjects with transfusion-dependent beta thalassemia who received at least one dose of the drug in the compassionate use phase including the post- marketing authorisation phase in those who continued to receive it.

Secondary outcomes

  1. subjects with comorbidities, number of participants with treatment-related adverse events as assessed by CTCAE v4.0"

    Time frame: 12-week interval period of luspatercept treatment.

    To evaluate safety of luspatercept in subjects with comorbidities that were exclusion criteria in formal clinical trials

  2. subjects with comorbidities, number of participants with treatment-related adverse events as assessed by CTCAE v4.0"

    Time frame: 12-week interval period of luspatercept treatment.

    To evaluate tolerability of luspatercept in subjects with comorbidities that were exclusion criteria in formal clinical trials

Other outcomes

  1. endocrinological changes

    Time frame: 52-week interval period of luspatercept treatment.

    Number of subjects who developed endocrinologicalchanges (alterations in frequency and duration of menstrual cycle, alterations in sexual function in men, thyroid dysfunction etc )

  2. thromboembolic events

    Time frame: 52-week interval period of luspatercept treatment.

    New cases of thromboembolic events

  3. factors positively affect drug response

    Time frame: 52-week interval period of luspatercept treatment.

    This outcome will assess the clinical, haematological, and biochemical factors that are positively associated with a favourable drug response to luspatercept, defined as a ≥33% reduction in transfusion burden sustained for at least 12 consecutive weeks during the 52-week treatment period.

    Factors evaluated will include:

    • Baseline haemoglobin level
    • Serum erythropoietin concentration
    • Reticulocyte count
    • Baseline transfusion burden

  4. factors negatively affect drug response

    Time frame: 52-week interval period of luspatercept treatment.

    This outcome will evaluate clinical, haematological, biochemical, or genetic factors that are **associated with a poor or absent response** to luspatercept treatment.

    Non-response will be defined as failure to achieve a ≥33% reduction in transfusion burden for at least 12 consecutive weeks during the 52-week treatment period.

    The following factors will be assessed as potentially associated with a negative response to treatment:

    High baseline transfusion burden Elevated baseline serum erythropoietin levels Lack of reticulocyte increase during treatment Presence of chronic comorbidities (e.g., liver disease, endocrine disorders)

  5. become transfusion independent while taking the drug

    Time frame: 52-week interval period of luspatercept treatment.

    Number of subjects who have not had red blood cell transfusions for at least eight consecutive weeks during treatment

Sponsors and collaborators

Lead sponsor

Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia

Other

Registry information

Official study title

Observational Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the "Compassionate" Use Phase

Acronym: LUSPA001

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Apr 6, 2025
Registry last updated
Apr 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.